Based on this mechanism, we investigated whether the combination of PKCβ inhibitor enzastaurin and BTK inhibitor ibrutinib had synergistic anti-tumor effects in DLBCL. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.